Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5594087 | 0.89 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL3250290 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5594461 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1 | |
| SCHEMBL5594780 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL3263244 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5069876 | 0.83 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL5594429 | 0.82 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL5594093 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL215075 | 0.81 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5069882 | 0.81 | PTGS2 (0.67) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1479385-B1 | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | SEARLE LLC (US) | 2008-07-02 | — | — | EP | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2005-05-05 | — | — | US | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| US-20030220384-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. SEARLE & CO. (US) | 2003-11-27 | — | — | US | claimed |
| US-6613789-B2 | Especially for treating arthritis, pain and fever | G. D. SEARLE & CO. | 2003-09-02 | — | — | US | claimed |
| EP-0880504-B1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-04-02 | — | — | EP | claimed |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | G.D. SEARLE & CO. | 2003-02-20 | — | — | US | claimed |
| EP-0772600-B1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | claimed |
| CN-1253502-A | Method for preventing cardiovascular diseases using cyclooxygenase-2 inhibitor | SEARLE & CO (US) | 2000-05-17 | — | — | CN | claimed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| CN-100457183-C | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2009-02-04 | — | — | CN | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-7402603-B2 | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2008-07-22 | — | — | US | disclosed |
| EP-0880504-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997027181-A1 | HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-07-31 | — | — | WO | disclosed |
| EP-0772600-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5616601-A | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation | GD SEARLE & CO (US) | 1997-04-01 | — | — | US | disclosed |
| WO-1996003388-A1 | 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885 |
| US-20030036557-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HCK, IL4I1, AHR | PTGS2 98/4885PTGS1 117/4885 |
| US-20050096368-A1 | Heterocyclo-substituted imidazoles for the treatment of inflammation | HRH4, LTC4S, HCAR3 | PTGS2 150/4885PTGS1 201/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885 |
| US-20030220384-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.